Opendata, web and dolomites

3DLT SIGNED

3D Living Tissues

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 3DLT project word cloud

Explore the words cloud of the 3DLT project. It provides you a very rough idea of what is the project "3DLT" about.

predictive    corresponding    mln    clinical    composition    share    building    ink    forecast    ones    acquire    revenue    edge    markets    requests    equal    proprietary    oncological    companies    trials    cells    regenerative    time    cell    tests    2bln    node    yearn    feasibility    unreliable    expenditure    structure    drug    satisfy    industrial    jan    framework    commercial    asymp    data    drugs    undertaking    medicine    immuneonco    develops    connecting    prometheus    economic    remaining    once    ip    living    market    price    96    respect    fails    customers    resolution    estimating    commercialization    preclinical    alive    efficient    bioprinting    opportunity    40mln    cutting    ematik    reduce    care    entire    compartmentalization    vitro    uncomplete    business    2019    pharmacological    1st    strictly    lymph    human    printing    safety    deeply    asap    3dln    performed    wounds    molecules    immunotherapies    spends    contrary    expenditures    printed    5bln    cosmetic    pharma    animal    cancer    times    tissues    connect    strategy    rate       company    3d    excluding   

Project "3DLT" data sheet

The following table provides information about the project.

Coordinator
PROMETHEUS S.R.L. 

Organization address
address: VIA TRENTO 30
city: PARMA
postcode: 43122
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.prometheus3d.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROMETHEUS S.R.L. IT (PARMA) coordinator 50˙000.00

Map

 Project objective

Prometheus S.r.l. develops and markets 3D human like tissues for regenerative medicine and pharmacological tests. A proprietary 3D Bioprinting Technology enables Prometheus to make use of human living cells as ink, to building up 3D tissues equal for structure and features to the human ones. The human living cells are printed by a strictly controlled process with high resolution, remaining alive during the entire printing process and for a long time beyond. The cutting edge new tissues satisfy the requests of pharma/cosmetic companies to reduce R&D expenditures and times for new products commercialization. Prometheus will go-to-market in Jan 2019 with its 1st product: Ematik, for wounds care. In this framework, Prometheus is undertaking a new business opportunity: a 3D Lymph Node (3DLN) for the testing of new immunotherapies against cancer. The 96% of oncological drugs efficient/safety in preclinical tests, fails human clinical trials, with a 2,5Bln$ expenditure/drug. This high failure rate is due to in vitro tests performed with current unreliable tissues: uncomplete, with different cell composition and compartmentalization respect to the corresponding human once. Contrary, Prometheus’ 3D Lymph Node is equal to the human one for composition, structure and functionality, providing more predictive data. Each company tests 80 new molecules/year and spends ≈4 Mln$ for in vitro tests, excluding animal testing (≈4 Mln$). Market of products for immuneonco testing is estimated in 2Bln€. According to key topics, all potential EU customers yearn to find on the market, asap, at any price, a 3D Lymph Node as the one of Prometheus, whose features allow to rapidly acquire a 4% EU market share in 5 years (40Mln€). During the feasibility study we will assess 3DLN project economic feasibility, we will connect with potential customers, estimating deeply market share, defining a revenue forecast, connecting with industrial and commercial partners, define also an IP strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3DLT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "3DLT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More  

CodeAll (2019)

The development of an innovative toolkit for learning programming with the use of the Internet of Things sensors and actuators

Read More  

HIPERSIM (2019)

Automated, Fast Generation of High-Performance Instruction Set Simulators for Microprocessors

Read More